Agomelatine - Is it another reboxetine? Another case of publication bias

BJPsych Bulletin

Volumn 38, Issue 2, 2014, Pages 88-

  Gupta, Sumeet ^a  

^a The Royal College of Psychiatrists   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; REBOXETINE;

DEPRESSION; HUMAN; LETTER; PUBLISHING; DRUG EFFICACY; DRUG TOLERABILITY; UNITED STATES;

EID: 84973499918     PISSN: 20564694     EISSN: 20564708     Source Type: Journal    
DOI: 10.1192/pb.38.2.88     Document Type: Letter

References (4)

1. Whiting D, Cowen PJ. Drug information update: agomelatine. Psychiatrist 2013; 37: 356-8.
2. Koesters M, Guaiana G, Cipriani A, Becker T, Barbui C. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry 2013; 203: 179-87.
3. National Institute for Health and Clinical Excellence. Agomelatine for the Treatment of Major Depressive Episodes (Terminated Appraisal) (Technology Appraisal TA231). NICE, 2011.
4. Eyding D, Lelgemann M, Grouven U, Hrter M, Kromp M, Kaiser T, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010; 341: c4737.